A Single-Stranded Oligonucleotide Inhibits Toll-Like Receptor 3 Activation and Reduces Influenza A (H1N1) Infection.
TLR3
clathrin-mediated endocytosis
co-stimulatory molecules
cytokines
human monocyte-derived dendritic cells (MoDC)
influenza A
mice
single-stranded oligonucleotides
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
05
2019
accepted:
28
08
2019
entrez:
2
10
2019
pubmed:
2
10
2019
medline:
11
11
2020
Statut:
epublish
Résumé
The initiation of an immune response is dependent on the activation and maturation of dendritic cells after sensing pathogen associated molecular patterns by pattern recognition receptors. However, the response needs to be balanced as excessive pro-inflammatory cytokine production in response to viral or stress-induced pattern recognition receptor signaling has been associated with severe influenza A virus (IAV) infection. Here, we use an inhibitor of Toll-like receptor (TLR)3, a single-stranded oligonucleotide (ssON) with the capacity to inhibit certain endocytic routes, or a TLR3 agonist (synthetic double-stranded RNA PolyI:C), to evaluate modulation of innate responses during H1N1 IAV infection. Since IAV utilizes cellular endocytic machinery for viral entry, we also assessed ssON's capacity to affect IAV infection. We first show that IAV infected human monocyte-derived dendritic cells (MoDC) were unable to up-regulate the co-stimulatory molecules CD80 and CD86 required for T cell activation. Exogenous TLR3 stimulation did not overcome the IAV-mediated inhibition of co-stimulatory molecule expression in MoDC. However, TLR3 stimulation using PolyI:C led to an augmented pro-inflammatory cytokine response. We reveal that ssON effectively inhibited PolyI:C-mediated pro-inflammatory cytokine production in MoDC, notably, ssON treatment maintained an interferon response induced by IAV infection. Accordingly, RNAseq analyses revealed robust up-regulation of interferon-stimulated genes in IAV cultures treated with ssON. We next measured reduced IAV production in MoDC treated with ssON and found a length requirement for its anti-viral activity, which overlapped with its capacity to inhibit uptake of PolyI:C. Hence, in cases wherein an overreacting TLR3 activation contributes to IAV pathogenesis, ssON can reduce this signaling pathway. Furthermore, concomitant treatment with ssON and IAV infection in mice resulted in maintained weight and reduced viral load in the lungs. Therefore, extracellular ssON provides a mechanism for immune regulation of TLR3-mediated responses and suppression of IAV infection
Identifiants
pubmed: 31572376
doi: 10.3389/fimmu.2019.02161
pmc: PMC6751283
doi:
Substances chimiques
Oligonucleotides
0
Toll-Like Receptor 3
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2161Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
Copyright © 2019 Poux, Dondalska, Bergenstråhle, Pålsson, Contreras, Arasa, Järver, Albert, Busse, LeGrand, Lundeberg, Tregoning and Spetz.
Références
Sci Rep. 2018 Oct 26;8(1):15841
pubmed: 30367171
Nat Rev Immunol. 2010 Jun;10(6):403-14
pubmed: 20498667
Cell. 2016 Apr 21;165(3):656-67
pubmed: 27085913
Front Immunol. 2018 Jan 31;9:126
pubmed: 29445377
Microbes Infect. 2004 Aug;6(10):929-36
pubmed: 15310470
J Clin Invest. 2011 Jan;121(1):6-13
pubmed: 21206092
Curr Opin Virol. 2017 Jun;24:16-24
pubmed: 28414992
J Virol. 2012 Oct;86(20):10950-60
pubmed: 22875971
J Virol. 2012 Mar;86(6):2900-10
pubmed: 22258243
PLoS Pathog. 2006 Jun;2(6):e53
pubmed: 16789835
Curr Top Microbiol Immunol. 2013;370:241-57
pubmed: 22638836
J Virol. 2010 Feb;84(3):1414-22
pubmed: 19939920
PLoS One. 2011;6(10):e26050
pubmed: 22022504
Eur Respir J. 2016 Mar;47(3):954-66
pubmed: 26743480
Curr Top Microbiol Immunol. 2015;386:23-71
pubmed: 25078919
Mol Cell. 2003 Oct;12(4):805-16
pubmed: 14580333
Nature. 2016 May 11;534(7605):124-8
pubmed: 27251289
Annu Rev Immunol. 2018 Apr 26;36:667-694
pubmed: 29677479
Cold Spring Harb Perspect Biol. 2014 Oct 09;7(1):a016246
pubmed: 25301932
Nat Protoc. 2014 Nov;9(11):2663-81
pubmed: 25321410
Vaccine. 2015 Sep 11;33(38):4954-61
pubmed: 26212006
J Clin Virol. 2013 Mar;56(3):226-31
pubmed: 23218952
PLoS Pathog. 2014 Jan;10(1):e1003848
pubmed: 24391503
Eur J Cell Biol. 2015 Jul-Sep;94(7-9):375-83
pubmed: 26095298
J Virol. 2018 Mar 28;92(8):
pubmed: 29386291
Curr Opin Immunol. 2018 Oct;54:80-85
pubmed: 29986838
J Virol. 2014 Nov;88(22):13269-83
pubmed: 25210166
Cold Spring Harb Perspect Biol. 2014 Aug 01;6(8):null
pubmed: 25085912
Nat Commun. 2017 Dec 5;8(1):1931
pubmed: 29203926
PLoS Pathog. 2012;8(3):e1002572
pubmed: 22412374
J Virol. 2015 Oct;89(20):10190-205
pubmed: 26223639
Blood. 2012 Jul 26;120(4):768-77
pubmed: 22700721
Science. 2006 Nov 10;314(5801):997-1001
pubmed: 17038589
Scand J Infect Dis. 2014 Dec;46(12):825-31
pubmed: 25195649
Eur J Pharmacol. 2017 Aug 15;809:178-190
pubmed: 28533172
Front Immunol. 2018 Jul 03;9:1521
pubmed: 30018617
Lancet. 2011 Apr 9;377(9773):1264-75
pubmed: 21435708
J Virol. 2006 Jul;80(13):6295-304
pubmed: 16775317
Cancer Immunol Immunother. 2011 Apr;60(4):457-66
pubmed: 21258790
Sci Rep. 2016 Jan 14;6:19428
pubmed: 26763587
Nat Rev Immunol. 2014 May;14(5):315-28
pubmed: 24762827
Immunity. 2015 Jul 21;43(1):15-28
pubmed: 26200010
Annu Rev Immunol. 2014;32:513-45
pubmed: 24555472